FDAsafety guidance72% confidence
Quantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) Trials
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as adenotonsillar hypertrophy treatment protocols.
Regulatory Analysis
Supporting Context
- Therapeutic area
- ENT · Surgical Intervention
- Sub-indication
- Ild
Related signal: Feasibility Study on IRE System for Adenotonsillar Hypertrophy in Children